Home › Funds › Candriam S.C.A. › REGN
Candriam S.C.A. position in REGN
REGENERON PHARMACEUTICALS · Health Care
Candriam S.C.A. reported holding 173,146 shares of REGN (REGENERON PHARMACEUTICALS) in its Q3 2026 13F filing — a position valued at US$131.8M, representing 0.59% of its reported portfolio and ranking #33 among its reported holdings. Candriam S.C.A. has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Candriam S.C.A.'s REGN position evolved
Candriam S.C.A. first disclosed a stake in REGN in Q3 2023 at 290,310 shares (US$238.9M). The position peaked in Q3 2024 at 252,525 shares, worth US$265.5M. Across 13 filings, Candriam S.C.A. increased the stake 5 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 173,146 shares valued at US$131.8M — a reduction of -22,528 shares quarter over quarter.. Notable position changes include a 26% increase in Q3 2024 (shares fell 32% over the following quarter), a 34% trim in Q2 2025 (shares rose 8% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 290.31K | $238.91M | New |
| Q4 2023 | 241.62K | $212.22M | Reduce |
| Q1 2024 | 217.77K | $209.60M | Reduce |
| Q2 2024 | 200.71K | $210.94M | Reduce |
| Q3 2024 | 252.53K | $265.45M | Add |
| Q4 2024 | 261.50K | $186.27M | Add |
| Q1 2025 | 214.94K | $136.32M | Reduce |
| Q2 2025 | 142.21K | $74.66M | Reduce |
| Q3 2025 | 169.50K | $95.30M | Add |
| Q4 2025 | 205.33K | $158.50M | Add |
| Q1 2026 | 186.39K | $144.01M | Reduce |
| Q2 2026 | 195.67K | $121.89M | Add |
| Q3 2026 | 173.15K | $131.77M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About REGN and 13F data
REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 29 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), Franklin Resources (US$2.75B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding REGN
- Dodge & Cox 4.87M sh · $3.04B · Q2 2026
- DODGE & COX 4.87M sh · $3.04B · Q2 2026
- Franklin Resources 2.95M sh · $2.75B · Q3 2026
- Nuveen, LLC 1.96M sh · $1.48B · Q3 2026
- LOOMIS SAYLES & CO L P 1.72M sh · $1.30B · Q3 2026
More on Candriam S.C.A.
FAQ
How long has Candriam S.C.A. held REGN?
Candriam S.C.A. has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Candriam S.C.A.'s current position in REGN?
As of Q3 2026, Candriam S.C.A. holds 173.15K shares of REGN (REGENERON PHARMACEUTICALS), valued at $131.77M, representing 0.59% of its reported portfolio and ranking #33.
Has Candriam S.C.A. been buying or selling REGN?
In the latest 13F filing (Q3 2026), Candriam S.C.A. reduced its position in REGN. The position peaked in Q3 2024 at 252.53K shares.
Which other funds hold REGN?
Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, Franklin Resources, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.